European experience of cladribine tablets in elderly patients with multiple sclerosis: Could it be the last treatment?

Background Recent studies support the need for early and intensive disease-modifying treatment (DMT) for patients with multiple sclerosis (PWMS). Abrupt DMT withdrawal may risk disease reactivation. Recent studies showed that MS disease activity was not rare after DMT withdrawal for PWMS aged >45/55...

詳細記述

書誌詳細

主要な著者:	Jérôme de Seze, Chiara Zecca, Giovanni Castelnovo, Xavier Ayrignac, Patrick Vermersch, Claudio Gobbi, Giulia Mallucci, Clarisse Carra-Dallière, Pierre Labauge, Kévin Bigaut, Laurent Kremer, Nicolas Collongues, Livia Lanotte, Eric Thouvenot, Christine Ernon, Dominique Dive
フォーマット:	Artigo
言語:	Inglês
出版事項:	SAGE Publishing 2025-01-01
シリーズ:	Multiple Sclerosis Journal - Experimental, Translational and Clinical
オンライン･アクセス:	https://doi.org/10.1177/20552173251321810
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!